RIPE-KG · Version 1.1.0 · Resource
ripekg:work/10.1093%2Fcid%2Fciac345
https://w3id.org/ripe/ripe-kg/work/10.1093%2Fcid%2Fciac345
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1016%2Fj.nmni.2025.101692Homologous and heterologous booster of COVID-19 vaccines: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/10.1093%2Fcid%2Fciac345Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial |
ripekg:work/10.1093%2Fcid%2Fciac345Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial |
prism:doi |
10.1093/cid/ciac345 |
ripekg:work/10.1093%2Fcid%2Fciac345Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial |
dcterms:title |
Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial |
ripekg:work/10.1093%2Fcid%2Fciac345Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial |
rdf:type |
node1 |
ripekg:work/10.1093%2Fcid%2Fciac345Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1093%2Fcid%2Fciac345Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial |
rdf:type |
rdfs:Resource |
ripekg:work/10.1093%2Fcid%2Fciac345Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial |
rdf:type |
owl:Thing |
ripekg:work/10.1093%2Fcid%2Fciac345Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial |
rdf:type |
prov:Entity |
ripekg:work/10.1093%2Fcid%2Fciac345Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1093%2Fcid%2Fciac345Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial |
owl:sameAs |
https://semopenalex.org/work/W4280558095 |